The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Open accessAbstract
INTRODUCTION: Immediate-release (IR) formulation of linaclotide 290 μg improves abdominal pain and constipation (APC) in patients with irritable bowel syndrome (IBS) with constipation. Delayed-release (DR) formulations were developed on the premise that targeting the ileum (delayed-release formulation 1 [DR1]) or ileocecal junction and cecum (MD-7246, formerly DR2) would modulate linaclotide's secretory effects while preserving pain relief effects. METHODS: This phase 2b study randomized patients with IBS with constipation to placebo or 1 of 7 once-daily linaclotide doses (DR1 30, 100, or 300 μg; MD-7246 30, 100, or 300 μg; or IR 290 μg) for 12 weeks. Key efficacy endpoints were change from baseline in abdominal pain and complete spontaneous bowel movement frequency, and 6/12-week combined APC+1 responder rate. RESULTS: Overall, 532 patients were randomized; mean age was 45.1 years, and most were women (83.3%) and White (64.7%). All linaclotide DR1 and MD-7246 groups experienced greater improvements in abdominal pain from baseline and vs placebo throughout treatment. Linaclotide DR1 and IR led to numerically greater improvements from baseline in complete spontaneous bowel movement frequency and higher APC+1 responder rates compared with placebo; MD-7246 results were similar to placebo. Diarrhea was the most common adverse event with DR1 and IR; rates were similar between MD-7246 and placebo. DISCUSSION: Altering the site of drug delivery in the intestine might uncouple linaclotide's pain relief from secretory effects. Persistent, modest abdominal pain improvement with limited impact on bowel symptom parameters, as seen across MD-7246 doses, warrants further study of MD-7246 as a novel treatment for abdominal pain, regardless of IBS subtype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An RCT of delayed-release linaclotide, with action confined to the ileo-caecal region of the gastrointestinal tract, demonstrated significant effects on abdominal pain, with lower rates of diarrhoea than conventionrelease linaclotide.165”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [165]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Self-citationFunctional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV
Drossman, D. A. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.032 · Cited by 2,430
The functional gastrointestinal disorders and the Rome III process
Drossman, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.008 · Cited by 2,416
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Altered rectal perception is a biological marker of patients with irritable bowel syndrome
Mertz, H., Naliboff, B., Munakata, J., Niazi, N., & Mayer, E. A. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90267-8 · Cited by 989
Tolerance for Rectosigmoid Distention in Irritable Bowel Syndrome
Whitehead, W. E., Holtkotter, B., Enck, P., Hoelzl, R., Holmes, K. D., Anthony, J., Shabsin, H. S., & Schuster, M. M. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90332-u · Cited by 593
Chey, W. D., Lembo, A. J., Lavins, B. J., Shiff, S. J., Kurtz, C. B., Currie, M. G., MacDougall, J. E., Jia, X. D., Shao, J. Z., Fitch, D. A., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.254 · Cited by 463
Self-citationAmerican College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
Self-citationRao, S., Lembo, A. J., Shiff, S. J., Lavins, B. J., Currie, M. G., Jia, X. D., Shi, K., MacDougall, J. E., Shao, J. Z., Eng, P., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.255 · Cited by 384
Self-citationMechanisms of hypersensitivity in IBS and functional disorders
Azpiroz, F., Bouin, M., Camilleri, M., Mayer, E. A., Poitras, P., Serra, J., & Spiller, R. C. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00875.x · Cited by 354
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
“Unfortunately, a meta-analysis of”
Chronic Visceral Pain: New Peripheral Mechanistic Insights and Resulting Treatments
Ford, A. C., Vanner, S. J., Kashyap, P., & Nasser, Y. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.045 · Cited by 93
Chang, L., Lacy, B. E., Moshiree, B., Kassebaum, A., Abel, J. L., Hanlon, J., Bartolini, W., Boinpally, R., Bochenek, W., Fox, S. M., et al. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001334 · Cited by 56
“This trial enrolled patients with IBS-C based on the Rome III diagnostic criteria for consistency with the validating trial for the DIBSS-C (23,33).”
MethodSelf-citationNanocrystalline Cellulose Cures Constipation via Gut Microbiota Metabolism
Wang, M., Cha, R., Hao, W., Du, R., Zhang, P., Hu, Y., & Jiang, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c05809 · Cited by 48
Review article: current and future treatment approaches for pain in IBS
Paine, P. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16550 · Cited by 46
Metadata
- Authors
- Chey, W. D., Sayuk, G. S., Bartolini, W., Reasner, D. S., Fox, S. M., Bochenek, W., Boinpally, R., Shea, E., Tripp, K., & Borgstein, N.
- Affiliations
- Michigan Medicine (US)
- Washington University in St. Louis (US)
- Ironwood Pharmaceuticals (United States) (US)
- Imbria Pharmaceuticals, Boston, Massachusetts, USA;
- AbbVie (United States) (US)
- Cyclerion (United States) (US)
- Corresponding author
- Bartolini, Wilmin
- Venue
- American Journal of Gastroenterology
- Published
- 2020-10-15
- Volume
- 116
- Issue
- 2
- Pages
- 354-361
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- PMC
- PMC8279899
- OpenAlex
- W3092931770
- Cited by
- 41
- References
- 27
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 18 · 2023: 1 · 2022: 5 · 2021: 9
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-nd
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- linaclotide, irritable bowel syndrome with constipation, delayed-release formulation, abdominal pain, diarrhea, once-daily dosing
- MeSH terms
- Guanylyl Cyclase C Agonists, Adult, Constipation, Defecation, Delayed-Action Preparations, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Peptides, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation. https://app.cochat.ai/papers/10.14309/ajg.0000000000000967
- The paper
- Chey, W. D., Sayuk, G. S., Bartolini, W., Reasner, D. S., Fox, S. M., Bochenek, W., Boinpally, R., Shea, E., Tripp, K., & Borgstein, N. (2021). Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000000967
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.